Loading
Galectin Therapeutics Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 09 Feb 2026.
Galectin Therapeutics Inc: what insiders have been doing
This page follows insider dealings at Galectin Therapeutics Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 10 insiders published 48 filings.
On the market, 2 insiders bought (3 purchases totalling €19k) while 3 insiders sold (14 sales totalling €633k). The totals do not cover 6 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 2 senior executives. At €182k, the sale published on 12 November 2025 by 10X Fund, L.P. is the largest of the period.
In all, 2 purchases were made within 30 days of a purchase by another insider of the company. Purchases made close together by different insiders form what is called a cluster. The last insider purchase was made public on 9 February 2026, 251 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (5,458 companies, median 22 filings), a count of 48 filings is above the norm. Since 2016, the database holds 41 purchases and 28 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of -30.8 m USD.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
183
Thresholds
n/a
Buy Volume
€247,540
41 ops. · all time
Sell Volume
€1M
28 ops. · all time
Who traded when
BuySaleKhurram Jamil8 sales
Harold H. Shlevin1 buy3 sales
Kary Eldred4 buys
10X Fund, L.P.3 sales
Freeman Kevin d3 buys
Zordani Richard A. Jr.1 buy
Since the insiders bought
- -19.9%Entry US$2.76 · Close at T+90 US$2.21
- -29.8%Entry US$4.03 · Close at T+90 US$2.83
- +246.2%Entry US$1.17 · Close at T+365 US$4.05
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.93
Analyst consensus
1 analysts1.00/5
US$11.00Target US$11.00(+180%)US$11.00
Income statement
EBITDA-US$23.5M
Net income-US$30.8M0.0% margin
Valuation
Beta0.39
Balance sheet & cash
Market capUS$396.3M
Total debtUS$133.8M
Free Cash Flow-US$23.9M
Profitability & ownership
ROA-64.2%
% insiders53.1%
% institutions15.7%
Last declaration on 4 August 2026
Declarations183 total
31,825,235 shares@ US$3.0023.98% mcap83.8% of flowCommon StockSEC:0001133416-26-000065:0
2,550,932 shares@ US$4.052.60% mcap9.1% of flowCommon StockSEC:0001133416-26-000065:1
16,250 shares@ US$5.12520.021% mcap12.6% of flowCommon StockSEC:0001133416-26-000063:1
16,250 shares@ US$3.040.013% mcap7.5% of flowCommon StockSEC:0001133416-26-000063:0
47,467 sharesCommon StockSEC:0001133416-26-000059:5
7,732 sharesCommon StockSEC:0001133416-26-000061:0
2,037 sharesCommon StockSEC:0001133416-26-000059:0
2,037 sharesCommon StockSEC:0001133416-26-000059:1
2,533 sharesCommon StockSEC:0001133416-26-000059:2
2,533 sharesCommon StockSEC:0001133416-26-000059:3
47,467 sharesCommon StockSEC:0001133416-26-000059:4
22,268 sharesCommon StockSEC:0001133416-26-000061:2
22,268 sharesCommon StockSEC:0001133416-26-000061:3
7,732 sharesCommon StockSEC:0001133416-26-000061:1
22,268 shares@ US$5.03920.028% mcap100.0% of flowCOMMONSEC144:0001628280-26-045997
68,287 shares@ US$5.000.12% mcap51.8% of flowCommon StockSEC144:0001972481-26-000216
7,732 shares@ US$5.0026100.0% of flowCOMMONSEC144:0001628280-26-045766
7,557 sharesCommon StockSEC:0001133416-26-000057:0
7,557 sharesCommon StockSEC:0001133416-26-000057:1
8,125 shares@ US$3.13850.0074% mcap3.9% of flowCommon StockSEC144:0001972481-26-000208
568 shares@ US$1.230.0002% mcap0.1% of flowCommon StockSEC:0001133416-26-000055:0
568 shares@ US$3.10040.0005% mcap0.3% of flowCommon StockSEC:0001133416-26-000055:1
300 shares@ US$2.702.7% of flowCommon StockSEC:0001133416-26-000048:0
Canonical exit: 7 May 2026 (T+90)
13,158 shares@ US$3.040.0% of flowCommon StockSEC:0001133416-26-000020:0
84,000 shares0Common StockSEC:0001133416-26-000008:0
25 of 183 declarations
About Galectin Therapeutics Inc
Galectin Therapeutics Inc. (NASDAQ: GALT) is a United States-based clinical-stage biotechnology company listed on the NASDAQ market. The company is headquartered in Norcross, Georgia, in the Atlanta metropolitan area. It was founded in July 2000, originally as Pro-Pharmaceuticals, Inc., and later reoriented around galectin science, becoming a focused developer of therapies aimed at fibrotic, inflammatory, and malignant diseases. For French-speaking investors evaluating the name, Galectin should be viewed as a classic development-stage biotech: it has a science-driven pipeline, limited or no commercial revenue, and a business model highly dependent on clinical readouts, regulatory interactions, and access to capital.
Galectin’s core strategy is built around galectins, especially galectin-3, which the company believes play an important role in biological and pathological processes such as fibrosis, inflammation, and cancer progression. Its lead asset is belapectin, a therapeutic candidate being advanced primarily in metabolic dysfunction-associated steatohepatitis (MASH, previously NASH) cirrhosis and portal hypertension. This is the company’s most important value driver and the program most closely watched by the market. In addition to the lead liver-disease franchise, the company has disclosed earlier-stage development efforts in severe atopic dermatitis, moderate-to-severe plaque psoriasis, and combination immunotherapy approaches for advanced melanoma and other malignancies. As a result, Galectin’s competitive position is not based on an existing commercial portfolio, but on the potential differentiation of its galectin-targeting platform.
Read moreShow less
Geographically, the business is U.S.-centric, with its corporate base in Georgia and historical research ties to the Boston area. Its market position remains that of a small-cap specialty biotech competing in a crowded and highly uncertain development environment. The upside case rests on whether belapectin can establish meaningful clinical benefit in a high-unmet-need liver disease setting and whether management can translate that science into a viable regulatory and partnering path. The downside case is the usual one for single-asset-heavy biotechs: delays, equivocal data, funding pressure, and dilution risk.
Recent company updates have centered on the NAVIGATE program for belapectin. During 2025 and into 2026, management highlighted additional biomarker analyses, ongoing presentation activity at major liver-disease conferences, and continued dialogue with the FDA regarding next steps. The company also reported quarterly losses and a relatively modest cash position, reinforcing the importance of execution and financing discipline. For market participants tracking SEC Form 4 insider transactions, Galectin is also a name with regular insider-filing activity, which is typical for a closely followed U.S.-listed biotechnology issuer.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
